DOI QR코드

DOI QR Code

Fertility preservation for patients with gynecologic malignancies: The Korean Society for Fertility Preservation clinical guidelines

  • Lee, Sanghoon (Department of Obstetrics and Gynecology, Korea University College of Medicine) ;
  • Kim, Seul Ki (Department of Obstetrics and Gynecology, Seoul National University Bundang Hospital) ;
  • Hwang, Kyung Joo (Department of Obstetrics and Gynecology, Ajou University School of Medicine) ;
  • Kim, Tak (Department of Obstetrics and Gynecology, Korea University College of Medicine) ;
  • Kim, Seok Hyun (Department of Obstetrics and Gynecology, Seoul National University College of Medicine)
  • Received : 2017.02.27
  • Accepted : 2017.07.05
  • Published : 2017.12.31

Abstract

Fertility preservation plays a central role in cancer care since an increasingly large number of cancer patients are surviving as a result of improvements in diagnostic and therapeutic strategies. Physicians who take part in the initial diagnosis and management of gynecologic cancer should understand the importance of fertility preservation. Since indications for fertility preservation are limited to early-stage gynecologic cancer, a surgeon must carefully consider each indication. Before performing fertility-sparing surgery, health professionals should compare its oncologic and pregnancy outcomes with those of other standard treatments. Individualized treatment strategies should be delivered depending on the patient's situation, and physicians should provide timely information and appropriate counseling.

Keywords

References

  1. Lee SJ, Schover LR, Partridge AH, Patrizio P, Wallace WH, Hagerty K, et al. American Society of Clinical Oncology recommendations on fertility preservation in cancer patients. J Clin Oncol 2006;24:2917-31. https://doi.org/10.1200/JCO.2006.06.5888
  2. National Comprehensive Cancer Network. Adolescent and Young Adult (AYA) Oncology version 2.2017: NCCN clinical practice guidelines in oncology (NCCN guidelines) [Internet]. Fort Washington: National Comprehensive Cancer Network; 2017 [cited 2017 Aug 14]. Available from: https://www.nccn.org/professionals.
  3. National Cancer Center. Annual report of cancer statistics in Korea in 2012. Sejong: Ministry of Health and Welfare; 2014.
  4. Lee S, Song JY, Ku SY, Kim SH, Kim T. Fertility preservation in women with cancer. Clin Exp Reprod Med 2012;39:46-51. https://doi.org/10.5653/cerm.2012.39.2.46
  5. Hwang JH, Yoo HJ, Park SH, Lim MC, Seo SS, Kang S, et al. Association between the location of transposed ovary and ovarian function in patients with uterine cervical cancer treated with (postoperative or primary) pelvic radiotherapy. Fertil Steril 2012;97:1387-93.e1-2. https://doi.org/10.1016/j.fertnstert.2012.02.052
  6. National Comprehensive Cancer Network. Cervical cancer version I.2017: NCCN clinical practice guidelines in oncology (NCCN guidelines) [Internet]. Fort Washington: National Comprehensive Cancer Network; 2016 [cited 2017 Aug 14]. Available from: https://www.nccn.org/professionals.
  7. Plante M, Gregoire J, Renaud MC, Roy M. The vaginal radical trachelectomy: an update of a series of 125 cases and 106 pregnancies. Gynecol Oncol 2011;121:290-7. https://doi.org/10.1016/j.ygyno.2010.12.345
  8. Willows K, Lennox G, Covens A. Fertility-sparing management in cervical cancer: balancing oncologic outcomes with reproductive success. Gynecol Oncol Res Pract 2016;3:9. https://doi.org/10.1186/s40661-016-0030-9
  9. Shepherd JH, Spencer C, Herod J, Ind TE. Radical vaginal trachelectomy as a fertility-sparing procedure in women with earlystage cervical cancer-cumulative pregnancy rate in a series of 123 women. BJOG 2006;113:719-24. https://doi.org/10.1111/j.1471-0528.2006.00936.x
  10. Hertel H, Kohler C, Grund D, Hillemanns P, Possover M, Michels W, et al. Radical vaginal trachelectomy (RVT) combined with laparoscopic pelvic lymphadenectomy: prospective multicenter study of 100 patients with early cervical cancer. Gynecol Oncol 2006;103:506-11. https://doi.org/10.1016/j.ygyno.2006.03.040
  11. Mathevet P, Laszlo de Kaszon E, Dargent D. Fertility preservation in early cervical cancer. Gynecol Obstet Fertil 2003;31:706-12. https://doi.org/10.1016/S1297-9589(03)00200-5
  12. Wang D, Yang J, Shen K, Xiang Y. Neoadjuvant chemotherapy followed by fertility-sparing surgery for women with stage IB1 cervical cancer. J Gynecol Oncol 2013;24:287-90. https://doi.org/10.3802/jgo.2013.24.3.287
  13. Bentivegna E, Gouy S, Maulard A, Chargari C, Leary A, Morice P. Oncological outcomes after fertility-sparing surgery for cervical cancer: a systematic review. Lancet Oncol 2016;17:e240-53. https://doi.org/10.1016/S1470-2045(16)30032-8
  14. Bentivegna E, Maulard A, Pautier P, Chargari C, Gouy S, Morice P. Fertility results and pregnancy outcomes after conservative treatment of cervical cancer: a systematic review of the literature. Fertil Steril 2016;106:1195-211.e5. https://doi.org/10.1016/j.fertnstert.2016.06.032
  15. Vasconcelos I, de Sousa Mendes M. Conservative surgery in ovarian borderline tumours: a meta-analysis with emphasis on recurrence risk. Eur J Cancer 2015;51:620-31. https://doi.org/10.1016/j.ejca.2015.01.004
  16. Lass A. The fertility potential of women with a single ovary. Hum Reprod Update 1999;5:546-50. https://doi.org/10.1093/humupd/5.5.546
  17. Korean Society of Gynecologic Oncology. Practice guideline for ovarian cancer version 3.0 [Internet]. Seoul: Korean Society of Gynecologic Oncology; 2015 [cited 2017 Aug 14]. Available from: http://www.sgo.or.kr.
  18. Schlaerth AC, Chi DS, Poynor EA, Barakat RR, Brown CL. Longterm survival after fertility-sparing surgery for epithelial ovarian cancer. Int J Gynecol Cancer 2009;19:1199-204. https://doi.org/10.1111/IGC.0b013e31819d82c3
  19. Kajiyama H, Shibata K, Mizuno M, Nawa A, Mizuno K, Matsuzawa K, et al. Fertility-sparing surgery in young women with mucinous adenocarcinoma of the ovary. Gynecol Oncol 2011;122:334-8. https://doi.org/10.1016/j.ygyno.2011.04.016
  20. Ditto A, Martinelli F, Lorusso D, Haeusler E, Carcangiu M, Raspagliesi F. Fertility sparing surgery in early stage epithelial ovarian cancer. J Gynecol Oncol 2014;25:320-7. https://doi.org/10.3802/jgo.2014.25.4.320
  21. National Comprehensive Cancer Network. Ovarian cancer including fallopian tube cancer and primary peritoneal cancer version I 2016: NCCN clinical practice guidelines in oncology (NCCN guidelines) [Internet]. Fort Washington: National Comprehensive Cancer Network; 2016 [cited 2017 Aug 14]. Available from: https://www.nccn.org/professionals.
  22. Satoh T, Hatae M, Watanabe Y, Yaegashi N, Ishiko O, Kodama S, et al. Outcomes of fertility-sparing surgery for stage I epithelial ovarian cancer: a proposal for patient selection. J Clin Oncol 2010;28:1727-32. https://doi.org/10.1200/JCO.2009.24.8617
  23. Fruscio R, Ceppi L, Corso S, Galli F, Dell'Anna T, Dell'Orto F, et al. Long-term results of fertility-sparing treatment compared with standard radical surgery for early-stage epithelial ovarian cancer. Br J Cancer 2016;115:641-8. https://doi.org/10.1038/bjc.2016.254
  24. Park JY, Kim DY, Suh DS, Kim JH, Kim YM, Kim YT, et al. Outcomes of fertility-sparing surgery for invasive epithelial ovarian cancer: oncologic safety and reproductive outcomes. Gynecol Oncol 2008;110:345-53. https://doi.org/10.1016/j.ygyno.2008.04.040
  25. Lee SW, Lee TS, Hong DG, No JH, Park DC, Bae JM, et al. Practice guidelines for management of uterine corpus cancer in Korea: a Korean Society of Gynecologic Oncology Consensus Statement. J Gynecol Oncol 2017;28:e12. https://doi.org/10.3802/jgo.2017.28.e12
  26. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013;63:11-30. https://doi.org/10.3322/caac.21166
  27. Crissman JD, Azoury RS, Barnes AE, Schellhas HF. Endometrial carcinoma in women 40 years of age or younger. Obstet Gynecol 1981;57:699-704.
  28. Park JY, Nam JH. Progestins in the fertility-sparing treatment and retreatment of patients with primary and recurrent endometrial cancer. Oncologist 2015;20:270-8. https://doi.org/10.1634/theoncologist.2013-0445
  29. Gallup DG, Stock RJ. Adenocarcinoma of the endometrium in women 40 years of age or younger. Obstet Gynecol 1984;64:417-20.
  30. Korean Society of Gynecologic Oncology. Practice guideline for uterine corpus cancer version 3.0 [Internet]. Seoul: Korean Society of Gynecologic Oncology; 2015 [cited 2017 Aug 14]. Available from: http://www.sgo.or.kr.
  31. National Comprehensive Cancer Network. Uterine neoplasms version I.2017: NCCN clinical practice guidelines in oncology (NCCN guidelines) [Internet]. Fort Washington: National Comprehensive Cancer Network; 2016 [cited 2017 Aug 14]. Available from: https://www.nccn.org/professionals.
  32. Ramirez PT, Frumovitz M, Bodurka DC, Sun CC, Levenback C. Hormonal therapy for the management of grade 1 endometrial adenocarcinoma: a literature review. Gynecol Oncol 2004;95:133-8. https://doi.org/10.1016/j.ygyno.2004.06.045
  33. Tangjitgamol S, Manusirivithaya S, Hanprasertpong J. Fertilitysparing in endometrial cancer. Gynecol Obstet Invest 2009;67:250-68. https://doi.org/10.1159/000209324
  34. Erkanli S, Ayhan A. Fertility-sparing therapy in young women with endometrial cancer: 2010 update. Int J Gynecol Cancer 2010;20:1170-87. https://doi.org/10.1111/IGC.0b013e3181e94f5a
  35. SGO Clinical Practice Endometrial Cancer Working Group, Burke WM, Orr J, Leitao M, Salom E, Gehrig P, et al. Endometrial cancer: a review and current management strategies. Part II. Gynecol Oncol 2014;134:393-402. https://doi.org/10.1016/j.ygyno.2014.06.003
  36. Sun C, Chen G, Yang Z, Jiang J, Yang X, Li N, et al. Safety of ovarian preservation in young patients with early-stage endometrial cancer: a retrospective study and meta-analysis. Fertil Steril 2013;100:782-7. https://doi.org/10.1016/j.fertnstert.2013.05.032
  37. Wright JD, Buck AM, Shah M, Burke WM, Schiff PB, Herzog TJ. Safety of ovarian preservation in premenopausal women with endometrial cancer. J Clin Oncol 2009;27:1214-9. https://doi.org/10.1200/JCO.2008.19.8150
  38. Gallos ID, Yap J, Rajkhowa M, Luesley DM, Coomarasamy A, Gupta JK. Regression, relapse, and live birth rates with fertility-sparing therapy for endometrial cancer and atypical complex endometrial hyperplasia: a systematic review and metaanalysis. Am J Obstet Gynecol 2012;207:266.e1-12.

Cited by

  1. Ovarian tissue cryopreservation and transplantation in patients with cancer vol.61, pp.4, 2017, https://doi.org/10.5468/ogs.2018.61.4.431
  2. Fertility-sparing management in women with endometrial and ovarian cancers vol.12, pp.6, 2018, https://doi.org/10.36290/xon.2018.049
  3. Investigation of Each Society for Fertility Preservation in Asia vol.10, pp.None, 2017, https://doi.org/10.3389/fendo.2019.00151
  4. The psychological importance of fertility preservation counseling and support for cancer patients vol.98, pp.5, 2017, https://doi.org/10.1111/aogs.13562
  5. Comparison between Slow Freezing and Vitrification for Human Ovarian Tissue Cryopreservation and Xenotransplantation vol.20, pp.13, 2019, https://doi.org/10.3390/ijms20133346
  6. Molecular Mechanism and Prevention Strategy of Chemotherapy- and Radiotherapy-Induced Ovarian Damage vol.22, pp.14, 2017, https://doi.org/10.3390/ijms22147484
  7. Role of Stem Cells in the Ovarian Tissue Cryopreservation and Transplantation for Fertility Preservation vol.22, pp.22, 2021, https://doi.org/10.3390/ijms222212482
  8. Changes in telomere length and senescence markers during human ovarian tissue cryopreservation vol.11, pp.1, 2017, https://doi.org/10.1038/s41598-021-81973-3